Improve Biologic Modalities Manufacturing for mAb Readiness

Monoclonal antibodies (mAbs) are among the most widely used biologic therapies, with applications across oncology, autoimmune disorders and infectious diseases. This webinar explores key manufacturing considerations for reliable, scalable monoclonal antibody production.

Although mAbs are often considered one of the more predictable biologic modalities, successful development still requires careful planning across cell line selection, process optimization, purification, analytical characterization and scale-up. Maintaining product quality, process robustness and manufacturing readiness remains critical from early development through commercial supply.

In this webinar, attendees will gain a practical overview of the key development and manufacturing considerations for monoclonal antibodies. Topics will include cell line development and selection, upstream process optimization, downstream purification strategies and the analytical tools used to characterize product quality. Participants will also learn how standard purification approaches, including Protein A affinity chromatography and additional chromatography and filtration steps, help remove impurities while preserving product integrity.

The session will further explore why monoclonal antibodies are often viewed as one of the most manufacturable biologic modalities. Advances in cell line engineering, process optimization and scalable manufacturing technologies have enabled modern processes to achieve high productivity while supporting efficient clinical and commercial supply. Attendees will also gain insights into scale-up considerations, process robustness and the role experienced CDMO partners play in supporting successful technology transfer, validation and commercialization efforts.

Register for this webinar to learn how biologic modalities such as monoclonal antibodies can be developed and manufactured through reliable, scalable and compliant production strategies.

Speaker

Dave Briggs, PhD, MSAT Principal Scientist, Late Stage/Commercial, Avid Bioservices

Dave Briggs, PhD, brings extensive experience in biopharmaceutical manufacturing, spanning purification R&D, downstream process development, manufacturing operations, process validation and continued process verification. Throughout his career, he has supported the development, transfer, validation and commercialization of biologic processes, with a focus on translating scientific understanding into robust, scalable and compliant manufacturing solutions.

As a Principal Scientist in Manufacturing Science and Technology (MSAT), Late Stage/Commercial, at Avid Bioservices, Dave leads cross-functional initiatives supporting process performance qualification, lifecycle management, process monitoring and continuous improvement of commercial manufacturing processes. He is recognized for applying data-driven approaches to enhance process robustness, ensure regulatory compliance and drive operational excellence across the product lifecycle.

Dave holds a PhD in Molecular and Cellular Biology from the University of Arizona and a BS in Microbiology from Brigham Young University. His expertise spans downstream processing, chromatography, technology transfer, process validation, manufacturing science and continued process verification, with a passion for transforming complex technical challenges into practical solutions that enable reliable and efficient biologics manufacturing.

Message Presenter